Braftovi

Oman · access guide

How to access Braftovi from Oman, the named-patient import pathway, 2026

By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23

A Oman patient diagnosed with BRAF V600E-mutant advanced melanoma, or BRAF V600E-mutant metastatic colorectal cancer in the appropriate setting, may receive a prescription for Braftovi (encorafenib) from their treating medical oncologist. Braftovi is typically used in combination with Mektovi (binimetinib) in melanoma, and in combination with cetuximab in BRAF V600E mutant metastatic colorectal cancer. Braftovi is FDA-approved in the United States. In Oman, Braftovi may not be uniformly stocked across hospital pharmacies, which is why your oncologist may be coordinating a named-patient import pathway on your behalf.

This guide explains the legal pathway, what documentation your physician needs, typical timing and cost bands, and where Reserve Meds fits in.

The clinical situation

Braftovi is an oral selective BRAF kinase inhibitor. Eligibility requires molecular confirmation of a BRAF V600E (or V600K in melanoma) mutation. The manufacturer is Pfizer (following the Array BioPharma acquisition). Dosing is typically 450 mg orally once daily in melanoma (combined with binimetinib) or 300 mg once daily in colorectal cancer (combined with cetuximab). Monitoring includes skin surveillance for new primary cutaneous malignancies, QTc, uveitis symptoms, and liver enzymes. Your oncologist will confirm BRAF status and the combination partner appropriate to your tumour type.

Is Braftovi legally importable into Oman?

Yes, through Oman Ministry of Health and Prevention (MOHAP) named-patient import framework, with parallel coordination through the Department of Health Abu Dhabi where the administering physician is Abu Dhabi-licensed.

The framework rests on four anchors: (a) the medicine is approved by a recognised reference authority (FDA qualifies), (b) no clinically equivalent locally registered alternative is suitable for the patient, (c) the treating physician takes clinical responsibility for use, and (d) the importing party documents chain of custody from the US source to the administering facility. Applications are typically filed by the hospital's importing pharmacy on the physician's behalf.

How the pathway works, step by step

1. **Consultation with your treating oncologist.** The decision to prescribe Braftovi is clinical, based on BRAF status, tumour type, and planned combination partner. Your oncologist documents the rationale.
2. **Administering facility identification.** A Oman tertiary oncology centre with an importing pharmacy files on behalf of the physician.
3. **MOHAP named-patient application.** Your physician or the hospital's importing pharmacy files an application with MOHAP including clinical rationale, combination regimen, patient identifier, product details, and chain-of-custody plan.
4. **US-side sourcing.** Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure product from the manufacturer's authorised distribution chain under DSCSA.
5. **Temperature-controlled shipment.** Braftovi is a stable oral capsule; shipments travel with tamper-evident packaging and end-to-end documentation.
6. **Arrival and dispensing support.** Your oncologist remains the treating clinician. Reserve Meds coordinates re-supply ahead of cycle end to avoid treatment gaps.

What documentation your physician needs

Your physician will typically need to provide:

- A clinical rationale letter confirming BRAF status, tumour type, combination partner, prior therapies, and Braftovi as the indicated treatment
- Verification of their Oman medical licence (MOHAP or DOH Abu Dhabi)
- A current prescription naming the product, strength, and quantity
- Patient identifier (anonymised reference preferred)
- The planned treatment cadence (continuous daily therapy with monthly re-supply)

Reserve Meds provides a physician documentation kit bundling the templates MOHAP reviewers expect to see for oncology oral therapies under named-patient import, including combination regimens.

Costs and timing

Braftovi's US cash-pay drug-only reference price for a 30-day supply sits in an indicative 2026 drug-only range (delivered quote issued at intake) of roughly USD 13,000-15,000. Families should separately plan for the cost of the combination partner (binimetinib or cetuximab). Logistics, MOHAP documentation handling, and concierge coordination add incremental cost; Reserve Meds issues a full transparent quote at the start of intake.

Indicative timing for first shipment arrival after cohort intake opens is 7-14 days from the moment a complete MOHAP application is submitted. Subsequent re-supply cycles are generally faster once the pathway is established.

Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.

Reserve Meds's role

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Braftovi specifically, we provide:

- **Sourcing.** Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- **Documentation.** Regulatory documentation package for your physician and for MOHAP review, including combination regimen details.
- **Logistics.** Temperature-stable shipment and chain-of-custody coordination.
- **Concierge case lead.** A named point of contact for your family and your physician throughout the process.

What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating oncologist.

Frequently asked

Is this legal in Oman? Yes, when executed through the MOHAP named-patient framework with appropriate documentation. See our trust and compliance page.

Can Braftovi and Mektovi be imported together? Yes, the combination is standard of care in BRAF-mutant melanoma. We coordinate both components of the regimen under a single concierge case.

What about skin surveillance? BRAF inhibitors can cause new cutaneous malignancies; your oncologist will arrange periodic dermatology review. We coordinate supply, not clinical surveillance.

Will private insurance cover this? Cash-pay is the default. Some Oman private insurers reimburse named-patient imports on case-by-case approval; we supply documentation for your submission but do not process insurance claims directly.

Reserve Meds's role

US-based concierge coordinator for cross-border specialty medicine. We are not the prescriber, not the dispensing pharmacy, and not the manufacturer. All clinical decisions remain with your treating physician.

reservemeds.com · hello@reservemeds.com